Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Werte in diesem Artikel
DUBLIN, Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025512.html
SOURCE Alkermes plc
Ausgewählte Hebelprodukte auf Alkermes
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Alkermes
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Alkermes Aktie News
Alkermes Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Alkermes nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 31.05.19 | Alkermes Neutral | H.C. Wainwright & Co. | |
| 14.12.18 | Alkermes Underperform | Wolfe Research | |
| 07.08.18 | Alkermes Hold | Stifel, Nicolaus & Co., Inc. | |
| 06.06.18 | Alkermes Buy | B. Riley FBR, Inc. | |
| 16.10.17 | Alkermes Equal Weight | Barclays Capital |
